SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C. Wainwright’s 26th Annual Global Investment ConferenceFormat: Prese ...

公司财务状况 - 公司于2023年6月30日和2023年12月31日分别拥有1590万美元和3590万美元的现金及现金等价物[168,169] - 公司在2024年6月30日的现金及现金等价物为15.9百万美元，累计亏损为267.7百万美元[231] - 公司需要大量额外资金支持持续经营和发展战略，如果无法及时筹集资金可能会延迟或中止产品候选物的开发和商业化[232,233] - 与GeneFab的交易为公司提供了3,780万美元的额外资本,其中1,890万美元已于交割时收到,剩余1,890万美元预计将于2025年上半年收到[234] - 2024年上半年经营活动现金流出为20,027,000美元,主要由于23,314,000美元的净亏损以及其他非现金调整[236] - 2023年上半年经营活动现金流出为29,979,000美元,主要由于37,419,000美元的净亏损以及其他非现金调整[237] - 公司将继续积极寻求额外融资,但如果无法以可接受的条款获得资金支持,可能会被迫延迟、缩减或终止产品候选物的开发和商业化[242] 公司业务发展 - 公司于2023年6月8日完成与Dynamics Special Purpose Corp.的业务合并交易[164] - 公司于2023年8月7日完成与GeneFab的交易,出售了部分资产并获得3780万美元的对价[171,176] - 公司与Celest Therapeutics签订了合作和期权协议,授予Celest在中国大陆、香港、澳门和台湾地区开发SENTI-301A的独家权利[178] - 公司于2024年7月17日实施了1:10的股票反向拆分[180] - 公司于2024年8月2日收到纳斯达克的通知,已重新符合最低股价要求[181] - 公司于2024年8月3日与加州再生医学研究所(CIRM)签订了800万美元的资助协议,用于SENTI-202的临床开发[182] 财务数据 - 公司三个月和六个月期间的总营业费用分别为1,335.6万美元和2,965.7万美元[206][219] - 公司三个月和六个月期间的研发费用分别为915.1万美元和1,792.9万美元[205][218] - 公司三个月和六个月期间的管理费用分别为420.5万美元和1,172.8万美元[206][219] - 公司三个月期间确认了1,587万美元的GeneFab分租收入[214] 公司披露信息 - 公司将继续保持"新兴成长公司"的地位，直到满足以下条件之一：(1)自IPO以来的第5个财年结束、年收入达到12.35亿美元或成为大型加速成长公司；(2)发行超过10亿美元的非可转换债务[250] - 公司目前为"小型报告公司"，可享受一些信息披露的豁免政策，如只需提供两年的经审计财务报表[251] - 公司目前只有一个业务活动和一个可报告分部[252] - 作为"小型报告公司"，公司无需提供市场风险的量化和定性披露[253] 其他 - 公司前期股东可能获得最多20万股额外公司普通股,分两期等额发放,但第一期20万股的股价目标未达成,相关权利已被取消[244] - 公司管理层认为公司现有现金及现金等价物可能无法支持公司运营超过12个月,需要寻求额外融资[241] - 公司未来资本需求取决于多方面因素,包括产品候选物的开发进度和成本、监管审批、商业化活动等[241]

临床试验进展 - 公司宣布启动SENTI-202的第1期临床试验,用于治疗复发/难治性血液恶性肿瘤,包括急性髓性白血病[6] - 公司正在开发SENTI-301A用于治疗肝细胞癌,并计划在2024年第四季度在中国启动试点试验[7] 融资与资金情况 - 公司获得加州再生医学研究所(CIRM)800万美元的资助,用于SENTI-202的临床开发[5] - 截至2024年6月30日,公司持有1590万美元的现金和现金等价物,并预计将收到1890万美元的GeneFab交易应收款[9] 财务表现 - 2024年第二季度,研发费用为920万美元,较2023年同期增加,主要是为支持自有项目的生产成本[9] - 2024年第二季度,管理费用为420万美元,较2023年同期下降,主要是由于员工人数减少[9] - 2024年第二季度,净亏损为1120万美元,每股基本和稀释亏损为2.45美元[9] 公司运营 - 公司于2024年7月进行了1:10的股票反向拆分,以符合纳斯达克的最低股价要求[8] - 公司计划参加9月份的H.C. Wainwright全球投资大会和9-10月的Chardan遗传医学大会[10] - 公司正在与Celest、Spark Therapeutics和BlueRock Therapeutics等合作伙伴继续推进合作和战略伙伴关系[11]

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported fina ...

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines ("CIRM"). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant will ...

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (“CIRM”). Pursuant to the executed agreement with CIRM, the first tranche of the grant award is expected to be received in August 2024. The CIRM grant wil ...

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a one-for-ten (1-for-10) reverse stock split of Senti Bio’s common stock, par value $0.0001 per share (the “Common Stock”). The reverse stock split will take effect at 11:59 p.m. EDT on July 17, 2024, and ...

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio") , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a one-for-ten (1-for-10) reverse stock split of Senti Bio's common stock, par value $0.0001 per share (the "Common Stock"). The reverse stock split will take effect at 11:59 p.m. EDT on July 17, 2024, and S ...

SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the California Institute for Regenerative Medicines (“CIRM”) has awarded an $8 million grant to Senti Bio. The CIRM grant will support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen re ...

Senti Biosciences (NASDAQ:SNTI) stock is taking off on Tuesday alongside heavy pre-market trading of the preclinical biotechnology company’s shares this morning. That has more than 8.5 million shares of SNTI stock changing hands as of this writing. This is a massive jump over its daily average trading volume of about 239,000 shares. It also bears mentioning that the company’s float is 29.16 million units. The heavy trading this morning comes without any clear news from Senti Biosciences. That includes a lac ...